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ABSTRACT
Purpose When information is sparse, individual parameters de-
rived from a non-linear mixed effects model analysis can shrink to
the mean. The objective of this work was to predict individual
parameter shrinkage from the Bayesian information matrix (MBF).
We 1) Propose and evaluate an approximation of MBF by First-
Order linearization (FO), 2) Explore by simulations the relation-
ship between shrinkage and precision of estimates and 3) Evaluate
prediction of shrinkage and individual parameter precision.
Methods We approximated MBF using FO. From the shrinkage
formula in linear mixed effects models, we derived the predict-
ed shrinkage from MBF. Shrinkage values were generated for
parameters of two pharmacokinetic models by varying the
structure and the magnitude of the random effect and residual
error models as well as the design. We then evaluated the
approximation of MBF FO and compared it to Monte-Carlo
(MC) simulations. We finally compared expected and observed
shrinkage as well as the predicted and estimated Standard
Errors (SE) of individual parameters.
Results MBF FO was similar to MBF MC. Predicted and ob-
served shrinkages were close . Predicted and estimated SE
were similar.
Conclusions MBF FO enables prediction of shrinkage and SE of
individual parameters. It can be used for design optimization.
KEY WORDS bayesian fisher information matrix . non-linear
mixed effects model . optimal design . pharmacokinetics
ABBREVIATIONS
CL Clearance
CV Coefficient of Variation
FO First-Order linearization
IU International Units
Km Michaelis-Menten constant
MAP Maximum A Posteriori
MBF Bayesian Fisher Information Matrix
MC Monte-Carlo
MF Fisher Information Matrix
MIBF Individual Bayesian Fisher Information Matrix
MIF Individual Fisher Information Matrix
ML Maximum Likelihood
MONOLIX MOdèles NOn LInéaires à effets miXtes
NLMEM Non-Linear Mixed Effects Models
PK Pharmacokinetics
Q Intercompartmental clearance
RSE Relative Standard Errors
SE Standard Errors
Sh Shrinkage
V Volume of distribution
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INTRODUCTION
Pharmacokinetic (PK) data are usually analyzed using Non-
Linear Mixed Effect Models (NLMEM) originally proposed
by Sheiner et al. in the 70’s (1). NLMEM describe the PK
behavior of a drug in a population of subjects through
estimation of PK population parameters and their
between-subject variability using Maximum Likelihood
(ML) approach in software such as NONMEM (2) and
MONOLIX (3). Once population parameters are estimat-
ed, individual parameters can then be derived by a Bayesian
approach as, for instance, the Maximum A Posteriori (MAP),
by incorporating the information obtained from the popu-
lation in the individual estimation. High precision in indi-
vidual estimates is mandatory. Indeed, these parameters are
extensively used in drug development to investigate any
influence of the PK on the pharmacodynamic responses,
using the sequential PKPD approach. Individual PK pa-
rameters can also be a basis for investigating any influence
of physiological and demographic covariates on drug con-
centration and for determining whether that influence im-
plies a dose adjustment in a subset of the population (eg:
impact of cytochrome P450 genotypes on clearance), or in
clinical practice to individually adapt the dose and dosing
regimen via early individual parameter estimation and pre-
dictions (eg: therapeutic drug monitoring).
The informativeness of a dataset in parameter estimation is
a function of the number of subjects and of the number and
timing of the samples (4). Population analysis allows the use of
sparse sampling in large clinical trials, where few samples are
collected in each subject. Each sampling time must be chosen
carefully to be informative. To evaluate and optimize a pop-
ulation design, two approaches have been proposed. The first
approach is based on clinical trial simulation and estimation,
leading to a very time-consuming approach that limits the
evaluation to a few designs and makes optimization difficult
(5). As an alternative, methods based on a mathematical
derivation of the Fisher information Matrix (MF) have been
developed (6). The inverse of the MF is used to derive the
expected precision of estimation of the parameters for a given
design,MF being the lower bound of the variance-covariance
matrix of any unbiased estimator of the parameters (7). Design
optimization relies on the use of a criterion, such as the D-
optimality criterion, which consists in minimizing the deter-
minant of the inverse ofMF over the space of possible designs,
which is equivalent to reducing the expected variance-
covariance matrix. This methodology was originally
developed in classic non-linear regression and was first ex-
tended to NLMEM byMentré et al. (8) and Retout et al. (9). Its
use has been facilitated by the implementation of the
Individual MF (MIF) and Population MF (MPF) expressions in
PFIM, an R function for individual and population design
evaluation and optimization (10). This approach to popula-
tion design evaluation is now used in other software as an
alternative to PFIM, like PopED (11), PopDes (12), POPT
(13), and has been extended to adaptive or robust optimal
design in pharmacokinetic studies (14,15).
Although those software programs are very appealing for
deriving sparse sampling design associated with good preci-
sion of population parameter estimates, they do not take
into account the precision of the individual estimates by
MAP. Although Merlé et al. (17) proposed an approach to
predict the precision of the individual parameter estimates
based on an approximation of the Bayesian information
Matrix (MBF) in NLMEM using a First Order linearization
(FO), this has, to our knowledge, never been implemented in
such software. For example, the current version of PFIM
predicts the SE of individual estimates, but only for standard
non-linear regression, assuming all variances of random
effects to be null (16). The bias in the individual estimates
that can be induced by the low number of samples per
subject is also not taken into account in those optimal design
methodologies. Indeed, for a rich design, the a posteriori
distribution of each random effect is very narrow and cen-
tered around the true value (18,19). However, in the case of
a sparse design, with less information per subject, the a
posteriori distribution is more spread out, and the mean value
is close to 0. This problem of shrinkage (Sh) is well described
in linear mixed-effects methodology (20). In NLMEM, the
variations in the random effects distribution and their con-
sequences for model diagnostics have been highlighted re-
cently by Savic et al. (21).
The main objective of this work was to predict shrinkage
associated with a design using Bayesian methodology. We first
approximatedMBF using FO of the model proposed byMerlé
et al. in 1995 (17). From previous work by Fedorov (20) in
linear mixed effects modeling methodology, we derived a
predicted shrinkage from MBF FO. Shrinkage and SE of
random effects were then predicted and compared with ob-
served shrinkage and SE estimated using simulation studies.
We used two different PK models as examples. The
first is a simple one compartment PK model (22), where
different variability and uncertainty levels are considered
in order to evaluate the results in various situations.
The second is a two-compartment PK model with an
approximated target-mediated drug disposition drawn
from real clinical studies (23) and supposed to mimic
the complexity of some models commonly used in drug
development. Simulated data from those PK models
were analyzed using both NONMEM and MONOLIX.
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MATERIALS AND METHODS
Models and Notations
For a given individual, let y be the vector of n observed
concentrations at n sampling times ξ={t1,…,tn} and f be
the known function describing the PK model. So, y can be
described by y= f (θ,ξ)+ε where θ is the p-vector of individ-
ual PK parameters, θ=(θ1,…,θp)
T.
ϵ is the random error, following a normal distribution
with zero mean and variance Σ(θ,ξ). Σ(θ,ξ) is defined with an
additive part σinter and a proportional part σslope with Σ(θ,ξ)=
diag((σinter+σslope f (θ,ξ ))
2).
Considering N individuals i following the same PK model
structure, individual parameters θi are defined as θi=g(μ,ηi)
where μ is the vector of p fixed effects and ηi is the vector of
individual random effects ηi=(ηi1,…,ηip)
T. Random effects
ηi follow a normal distribution with zero-mean and variance
Ω. Here we assumed that Ω is a diagonal p×p matrix of
variances of random effects Ω=diag(ω1
2,…,ωp
2). We con-
sidered two models for g(μ, ηi): additive, where g(μ,ηi)=μ+
ηi, or exponential, where g μ; ηið Þ ¼ μeηi . The vector Ψ of
population parameters is composed of {μ1,…,μp,ω1
2,
…,ωp
2,σinter,σslope}. As in this work we focused on individual
parameter’s estimation, Ψ was supposed to be known or
previously estimated. By this approach we sought to avoid
any bias or distribution discrepancies in parameter distribu-
tion to only validate MBF approximation.
Individual Parameter Estimation
From a vector of observed concentrations y, individual pa-
rameters can be estimated by standard individual non-linear
regression. This approach does not take into account previ-
ous information. On the contrary, in NLMEM, individual
parameters are usually estimated by a Bayesian approach,
such as the MAP. As μ is known, estimating η is similar to
estimating θ. More precisely, the MAP estimate bη of η is
given by:
bη ¼ argmax p η
 y
  
ð1Þ
It can be also written, using Bayes theorem,
bη ¼ argmax
p y
η
 
 p ηð Þ
p yð Þ
0
@
1
A
¼ argmax log p y
η
  
þ log p ηð Þð Þ
 
ð2Þ
as p( y) is independent of η.
Bayesian Fisher Information Matrix
For individual estimation, in a non-linear model,
MIF for parameters θ is:
MIF θ; ξð Þ ¼ −Ey
∂2ln p y
θ
  
∂θ∂θT
0
@
1
A ð3Þ
For homoscedastic error, MIF is expressed as:
MIF θ; ξð Þ ¼ F θ; ξð Þ
T
Σ θ; ξð Þ−1F θ; ξð Þ ð4Þ
where F θ; ξð Þ ¼ ∂ f θ;ξð Þ∂θT :
For Bayesian estimation of the random effects, MBF is
defined by (22):
MBF ξð Þ ¼ −Eη
∂2log p η
y
  
∂η∂ηT
0
@
1
A
¼ −Eη E
y
η
∂2log p y
η
  
∂η∂ηT
0
@
1
A
0
@
1
A−Eη ∂
2log p ηð Þð Þ
∂η∂ηT
 
ð5Þ
In Eq. (5), MBF is a sum of 2 matrices respectively
representing individual and prior information. As p(η) is
normal, −Eη ∂
2 log p ηð Þð Þ
∂η∂ηT
 
¼ Ω−1. Also, noting the link be-
tween the first part of the equation and MIF, we have:
MBF ξð Þ ¼ Eη MIF g μ; ηð Þ; ξð Þð Þ þΩ−1 ð6Þ
We used two methods to compute MBF (17). An evalua-
tion by Monte-Carlo simulation (MBF MC), where a large
number of ηi are simulated from N(0, Ω) and the expectation
in Eq. (5) is computed as the empirical mean. MBF can also
be evaluated using FO linearization of the model around the
random effect in the expression of the likelihood. It can be
shown that MBF is then approximated by:
MBF ξð Þ ¼ Μ T F μ; ξð Þ
T
Σ μ; ξð Þ−1F μ; ξð ÞΜ þ Ω−1 ð7Þ
where M is an identity matrix (I) for additive random effects,
and Μ=diag(µ1,…,µp) for exponential random effects.
MBF is the expected information over all η. We can also
compute the Bayesian information Matrix for a given indi-
vidual (MIBF) which depends on its random effect. Using
FO, MIBF is approximated by:
MIBF η; ξð Þ ¼ ΘT F g μ; ηð Þ; ξð Þ
T
Σ g μ; ηð Þ; ξð Þ−1F g μ; ηð Þ; ξð ÞΘ þ Ω−1
ð8Þ
where Θ is an identity matrix for additive random effects,
and Θ=diag(θ1,…,θp) for exponential random effects.
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Predicted Shrinkage
Shrinkage in linear mixed effect models is well established
(24) and Fedorov in 2011 (20) proposed the matrix I–W for
its quantification. Assuming that the linear model is defined
as y=F(ξ)θ+ε, then, for individual estimation
bθML ¼ MIF ξð Þ−1F ξð ÞT y ð9Þ
where MIF(ξ)=F(ξ)
TΣ(ξ)−1F(ξ) (25). In both (20) and (24), it
is shown that the MAP estimate of θ can be expressed as
bθMAP ¼ MIF ξð Þ þ Ω−1
 −1
MIF ξð ÞbθML þ Ω−1μ
 
ð10Þ
By setting
W ξð Þ ¼ I− MIF ξð Þ þ Ω−1
 −1
Ω−1 ð11Þ
Then,
I−W ξð Þ ¼ MIF ξð Þ þ Ω−1
 −1
Ω−1 ð12Þ
Equation (10) becomes
bθMAP ¼ I−W ξð Þð ÞμþW ξð ÞbθML ð13Þ
W then quantifies the balance between prior and indi-
vidual information. Indeed, bθMAP ¼ bθML when W = I and
bθMAP ¼ μ when W = 0. We propose to extend this formula
in non-linear mixed-effect models where W is computed
from MBF as:
I−W ξð Þ ¼ MBF ξð Þ−1Ω−1 ð14Þ
As Ω is diagonal, the diagonal elements of I–W are the
ratio of the predicted estimated variance of the Bayesian
estimation and the a priori variance. WhenMBF
−1 is close to Ω
(no information), I–W is close to I. In this case, shrinkage is
expected to be high.
Simulation Study
Example 1
We used a simulated example inspired by similar method-
ology reported by Mentré et al. (22). This theoretical exam-
ple involved a one-compartment PK model with IV bolus
administration. The two parameters are volume of distribu-
tion (V) and clearance (CL). For a given dose D, the predic-
tion at time tj is:
f θ; t j
  ¼ D
θ1
exp
−θ2θ1 t j
 
ð15Þ
with θ1=V and θ2=CL.We assumedμV=0.2 IU, μCL=0.5 IU
and a dose D=1 IU. As this model is theoretical, we did not
consider any specific units. To compute the Fisher matrices in
various situations, we considered several scenarios with differ-
ent types of random effects models (ie: additive or exponential),
different types of residual error models (ie: additive or com-
bined) and different values for the random effects. No correla-
tion between parameters was assumed. All scenarios are given
in Table I. Scenarios were named with two letters, the first one
representing the type of random effect models and the second
one the type of residual error model (ie: a for additive, e for
exponential, and c for combined). The lower and upper-case
letters stand for low variance (Coefficient of Variation (CV) of
20%) and high variance (50% CV) of random effect, respec-
tively. For this example 1, we performed two simulations A and
B. Simulation A evaluates the use ofMBF in predicting shrink-
age for each scenario, the vector Ψ of population parameters
being considered as known and fixed at the true simulation
value. We defined a set of five possible sampling times: {0.05,
0.15, 0.3, 0.6, 1} and D-optimal designs with 2 to 5 samples
were derived considering the first (aa) scenario. These designs
are described in Table II. Simulation B compares predicted
versus observed shrinkages in a more realistic setting, incorpo-
rating the discrepancies due to the population parameter esti-
mation step as often encountered in a real estimation context.
This simulation B was performed for scenario ec using a
combined design with 2 groups of 50 and 150 subjects each
containing 5 and 2 samples per subject respectively, with
sampling times similar to those in simulation 1 (Table II).
An additional investigation using this example was
performed to explore the impact of MBF on design optimi-
zation and is presented in the Supplementary Materials I.
We compared the optimal design obtained with MBF and
MPF and computed the loss of efficiency associated with
each one.
Example 2
The second example is a more complex PK model, adapted
from the population pharmacokinetic model of an anti-
interleukin-6 receptor antibody used as rheumatoid arthritis
treatment (23). The PK model, established using a large
Table I Population Parameter Values for Each Scenario of Example 1
Scenario aa ac ea ec Ea Ec
Random effects
Form Add Add Exp Exp Exp Exp
ωV (CV%) 20 20 20 20 50 50
ωCL (CV%) 20 20 20 20 50 50
Residual error
σinter 0.15 0.15 0.15 0.15 0.15 0.15
σslope (CV%) 0 15 0 15 0 15
Add additive; Exp Exponential
2358 Combes, Retout, Frey and Mentré
phase III database, is a two compartment model with par-
allel first-order (linear) and Michaelis-Menten (non-linear)
elimination kinetics. With this model, the drug amounts in
the central (A1) and peripheral (A2) compartments were
described by the following differential equations:
dA1
dt
¼ −k10A1−k12A1 þ k21A2− C1V mK m þ C1 ð16Þ
dA2
dt
¼ k12A1−k21A2 ð17Þ
where k10, k12 and k21 are rate constants of drug exchanges
between the different compartments: k10 ¼ CLV1 , k12 ¼
Q
V1
and
k21 ¼ QV2 ; C1 is the concentration in the central compart-
ment: C1 ¼ A1V1 , where CL denotes the clearance, V1 is
the volume of distribution of the central compartment,
V2 is the volume of distribution of the peripheral com-
partment, Vm is the maximum elimination rate, Km is
the Michaelis constant, and Q is the intercompartmental
clearance.
The population parameter values are detailed in
Table III. A combined error model and exponential ran-
dom effects were used. As the FO approximation is appro-
priate only with small variances, for simplicity, we rounded
off fixed effect values and assumed 30% CV for between-
subject variability on CL, V1, V2 and Vm. A model with
high variance, as in the basic model developed by N. Frey et
al. (only full model with covariate described in (23)), and a
model with intermediate variabilities (80%CV on V2) were
also simulated without the covariate model and the results
are given in the Supplementary Materials II (Table SII and
Figure S1). Six repeated one-hour infusions every 4 weeks at
the dose of 8 mg/kg were assumed. Four different designs
were simulated, involving 10, 9, 4 or 2 samples per subject,
at the same sampling times, with 1,800 subjects. The design
with 10 samples was created by collecting 3 samples after
the first dose (end of infusion, 10 and 20 days), 3 pre-doses
samples before the 2nd, 3rd and 5th doses, and then 4
samples after the last dose (end of infusion, 20, 28 and
56 days after the last dose). The last sample (56 days after
the last dose) was removed for the 9-samples design. Using
the same sampling allocations, a peak and trough design was
applied after the first dose for the 2 samples per subject
design. From this last design, 2 sampling allocations after the
last dose (end of dose and 56 days after the last dose) were
added to create a 4 samples per subject design. Sample
allocations are detailed in Table IV.
Software and Analysis
For example 1, datasets were simulated using R 2.14.
NONMEM 7.0 and MONOLIX 4.0 were used to estimate
individual random effects and their precision of estimation
(estimated SE) given the model. We used two software pro-
grams as they are both extensively used and considered as
references in drug development for population analysis
using NLMEM. For simulation A, one dataset of 1,000
subjects was simulated per scenario and per design.
Population parameters estimation was skipped using specific
options in both software programs and only individual pa-
rameters were estimated as MAP. In NONMEM, popula-
tion parameters were specified to their true values by using
the option MAXEVAL = 0 (number of objective function
evaluations) (26), and individual parameters were estimated
Table II Sampling
Times of Example 1 Number of
samples
Sampling times
5 0.05, 0.15, 0.3, 0.6, 1
4 0.05, 0.3, 0.6, 1
3 0.05, 0.3, 0.6
2 0.05, 0.3
Table III Population
Parameter Values Used in
Example 2
Parameter Simulation value
μCL (l/d) 0.3
μV 1 (l)
4
μQ (l/d) 0.15
μV 2 (l)
3
μV m (mg/d)
6
μK m (μg/ml)
2
Random effects (CV%)
ωCL 30
ωV 1
30
ωV 2
30
ωV m
30
Residual error
σinter (μg/ml) 0.5
σslope (%) 30
Table IV Sampling Times of Example 2
Number of
samples
Sampling times (days)
10 0.06, 10, 20, 27.99, 82.02, 111.99, 140.06, 168, 196
9 0.06, 10, 20, 27.99, 82.02, 111.99, 140.06, 168, 160
4 0.06, 27.99, 140.06, 196
2 0.06, 27.99
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using the first order conditional estimation with interaction
method (FOCEI). In MONOLIX, the number of chains
and the number of iterations (K1 and K2) were specified
respectively at 5 chains, 800 and 300 iterations with fixed
population parameters. For simulation B, we simulated
1,000 datasets and estimated both population and individ-
ual parameters using the SAEM algorithm implemented in
MONOLIX.
In a first step, using the individual random effects esti-
mates given by NONMEM, we investigated the influence of
shrinkage on individual estimates and on estimated random
effects distribution. Then, in order to evaluate the expres-
sion of MBF with the FO approximation, we compared
Relative Standard Errors (RSE) computed with MBF FO
to MBF MC using the 1,000 simulated subjects. We also
compared the quantity of information provided by the 3
considered regressions (individual with MIF, population with
Ω and individual Bayesian with MBF). Ω defined the vari-
ance of the estimation yielded by Bayesian estimation with-
out any individual information, and is therefore an upper
bound of the variance of the individual Bayesian estimation.
Predicted shrinkage computed with MBF FO was compared
with observed shrinkage (Sh) on random effects estimated
with NONMEM and MONOLIX without population esti-
mation, and MONOLIX with population estimation.
Observed shrinkage for parameter k was defined as (21):
Shk ¼ 1−
var bηi;k
 
ω2k
ð18Þ
bηi;k being the estimated value of η, and var bηi;k
 
the
empirical variance, estimated by NONMEM or
MONOLIX. Note that in the case of very low shrinkage
Eq. (18) can produce negative values which were set to 0.
Although Savic et al. expressed shrinkage as the ratio of
standard deviations, the ratio of variances, which is more
usual in biostatistics, was used here. All thresholds and
values extracted from Savic et al. were converted to ratio
of variances in the present paper. Finally, using simulation
results, we compared each estimated individual SE with the
predicted SE obtained from the diagonal of MIBF
−1.
Datasets for example 2 were simulated with NONMEM
7.0, and the same options as for example 1 (simulation A)
were used for estimation with NONMEM 7.0 and
MONOLIX 4.0. We performed two steps similar to those
in the first example: we compared predicted vs observed
shrinkage and individual SE. MBF, MIF and shrinkage
computations were performed with R 2.14. This meth-
odology should be implemented in a future version of
PFIM. Meanwhile, the R code used to compute MBF,
SE, RSE and predicted shrinkage is given in Supplementary
Materials III.
RESULTS
Example 1
Shrinkage Impact on Individual Estimates
The simulated scenarios generated observed shrinkage values
that ranged from 0% to 69% for CL and from 0 to 52% for V.
All the shrinkage values are given in Table V for each scenario
and for each number of samples per subject for the two
software programs. The highest shrinkage was obtained for
2 samples per subject with a low variance for CL and V and a
combined error model. As NONMEM and MONOLOX
provide similar results, and as the observations for volume
are similar to those for clearance, only NONMEM results for
clearance are shown and discussed in the rest of this section.
Figure 1 presents individual parameter estimated with
NONMEM vs simulated parameters along with observed
shrinkage for each scenario and for each number of samples.
This figure also shows the distribution of estimated and sim-
ulated random effects. With small shrinkage (≈7% for clear-
ance, scenario ea with 5 samples), the estimated η distribution
(in red) is close to the simulated η distribution (in black) and
the simulated and estimated individual parameters are close to
the identity line. With 2 samples per subject with the same
scenario, the shrinkage increases to 20%. The simulated and
estimated η distributions remain relatively similar, as do the
simulated and estimated individual parameters. Changing the
form of the random effects from exponential to additive with
the same variance (20%CV) had nomajor effect on shrinkage
or parameter estimation. Changing the residual error from
additive to combined for the same scenario increased the
shrinkage to 69%. For this high shrinkage, the estimated η
distribution clearly shrank towards zero, and the estimated
individuals parameters deviated from the simulated values.
When the CV of exponential random effects was increased to
50% CV, individual random effects were very well estimated
whatever the design used. Thus, shrinkage for a combined
error model and 2 samples per subject decreased to 33%.
Evaluation of MBF FO Approximation
Predicted Relative Standard Errors (RSE) calculated from
MIF
−1,MBF
−1 with FO or MC, and Ω are reported for each
scenario in Fig. 2. FO approximated values from MBF
−1 were
very close to those using Monte-Carlo simulations, thus
validating the FO approximation in computing MBF
−1.
Similar values were found for low between-subject variability,
and only slight differences were observed, without exceed-
ing 5% for higher variances of random effects (scenarios
Ea, Ec). Note that as expected, predicted RSE increased
with decrease of information per subject. RSE approxima-
tions from MBF
−1 FO were always below the value of Ω
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and MIF
−1 RSE and those computed by MBF
−1 MC were
always smaller than or very close to Ω and MIF
−1. When
fewer samples per subject were collected, RSE predicted
byMBF
−1 increased less than when predicted by MIF
−1, show-
ing the advantages of such a Bayesian approach in individual
parameter estimates.
Optimal Design
In Supplementary Materials I, we compared the criteria
from MBF and MPF for 3420 designs. We found that the
optimal designs for Sh-optimality and population–optimal-
ity differed, and were {0.05, 0.75, 0.8} and {0.05, 0.35, 1},
respectively. Also, for each criterion (MBF or MPF) there was
a loss of efficiency when using the design optimal for the
other criteria (see Table SI).
Shrinkage Prediction
Figure 3 shows predicted vs observed shrinkage without pop-
ulation estimation with NONMEM and MONOLIX (simu-
lation A - 2 left columns) and with population estimation with
MONOLIX (simulation B - right column) for CL and V. For
simulation A, all the points were close to the identity line for
CL and V and for both software programs, indicating that the
computation of I–W proposed in Eq. (14) using MBF
−1 FO
predicts shrinkage very well across a large range of shrinkage
values whenΨ is known.When including the estimation of the
population parameters in the comparison, simulation B, the
predicted shrinkage value obtained for each parameter
corresponded to themedian of the distribution of the observed
shrinkages. The greatest difference between the observed and
predicted values did not exceed 20%. This validates the use of
MBF
−1 FO to predict shrinkage, even in a real context, includ-
ing estimation of the population parameters.
SE of Random Effects
SE from MIBF
−1 were computed and then compared with
estimated SE of individual random effects using NONMEM
and MONOLIX. The results are shown in Fig. 4. As
expected, SE decreased when the number of samples for each
subject increased, for the four methods. Adding a proportion-
al part in the residual error model led to an increase inmedian
SE. In the same way, changing random effects from additive
to exponential or increasing the value of their variance from
Table V Observed Shrinkage
Values with NONMEM and
MONOLIX of Example 1
Scenario Number of samples per patient Volume Clearance
NONMEM MONOLIX NONMEM MONOLIX
aa 2 1.77 3.39 17.41 17.31
3 1.55 3.08 8.62 8.64
4 0.92 2.45 6.22 6.24
5 0.10 0.10 5.76 5.76
ac 2 48.95 48.95 66.56 66.56
3 46.93 46.92 36.90 36.90
4 45.14 45.14 30.00 30.00
5 38.35 38.34 28.39 28.39
ea 2 1.91 1.91 20.11 20.11
3 1.19 1.19 11.42 11.42
4 0.77 0.77 9.05 9.05
5 0.54 0.54 7.11 7.11
ec 2 51.54 51.54 68.79 68.79
3 48.85 48.85 41.31 41.31
4 44.89 44.89 33.53 33.53
5 35.91 35.91 31.51 31.51
Ea 2 1.50 1.30 7.55 7.59
3 1.02 0.82 1.47 1.54
4 0.49 0.28 0.00 0.00
5 0.00 0.00 0.00 0.00
Ec 2 16.31 16.31 32.46 32.46
3 18.32 18.32 21.35 21.35
4 17.77 17.77 10.14 10.14
5 15.10 15.10 9.46 9.46
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20 to 50% CV led to an increase in SE. The MBF
−1 FO
predicted value was always near the median value computed
with MIBF
−1. Similar values were observed with NONMEM
and MONOLIX. Predicted SE fromMIBF
−1 were very close to
the estimated SE for all scenarios. In the case of a combined
error model, MONOLIX systematically estimated a wider
distribution of the SE of volume.
Example 2
Shrinkage Prediction
Figure 5 shows predicted vs observed shrinkage for each
parameter of the complex model and each design. The dots
were close to the identity line whatever the number of
Fig. 1 Example 1: Estimated vs
simulated clearance (CL) and
comparison of simulated and
estimated distribution of random
effects by scenario for 2 (left
columns) and 5 samples (right
columns) per subject. Indicated Sh
values are the observed Sh. For
the scatterplots, the horizontal
red line represents the population
value (μ) and the dotted black line
is the identity line. For η
distributions, the red and black
curves are respectively the
estimated η distribution and the
simulated distribution. The black
vertical line represents the
population mean of η, 0.
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samples per subject and the PK parameter. There was
slightly better agreement between the predicted shrink-
age and the shrinkage computed using MONOLIX
individual estimates than with the NONMEM estimates,
especially for CL for the 2 designs with the smaller
number of samples. In section II of the Supplementary
Material we report two simulations for which real var-
iability values of the basic model as well as intermediate
ones (see Table S1) were used to compare predicted
versus observed shrinkage. These simulations showed
some discrepancies between predicted and observed
shrinkage, especially for V2, and these discrepancies
increased with variability (see Fig. S1).
SE of Random Effects
Figure 6 shows the comparison of predicted vs observed
SE. As expected, SE decreased when the number of
samples per subject increased. Whatever the design
and the parameter, MIBF
−1 predictions were close to the
values estimated with NONMEM and MONOLIX.
SE computed by MBF
−1 FO were highly consistent with
the MIBF
−1 predictions.
DISCUSSION
We proposed a method to predict shrinkage using an ap-
proximation of MBF in NLMEM based on a FO lineariza-
tion and we evaluated it for a large range of shrinkage values
and from a simple linear PK model to a more complex non-
linear one. The approximatedMBF was very close to the one
obtained by Monte-Carlo simulations and the proposed
prediction method was shown to give a very good prediction
of observed shrinkage. Our investigations also highlight that
shrinkage is influenced by design (eg: number of samples per
subject and sample allocations), but also by the ratio be-
tween residual error and random effect variances, a small
ratio resulting in high shrinkage.
To the best of our knowledge, this is the first time that
shrinkage has been predicted using MBF in NLMEM. The
main publications regarding Bayesian design evaluation and
optimization in NLMEM were written by Merlé et al. (17)
and Mentré et al. (22) in the 90’s. The first paper focuses on
defining and simplifying the computation of three Bayesian
design criteria for several designs and PK models: the de-
terminant of MBF, the determinant of the pre-posterior
covariance matrix and the expected information provided
Fig. 2 Example 1: relative standard errors of volume and clearance computed from MIF
−1 (circle), MBF
−1 with FO (blue diagonal cross “x”) or MC (blue
vertical cross “+”), along with SD computed from M (similar to RSE in the absence of any individual data-red horizontal line).
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by an experiment. These criteria indicate the relevance of
computing the matrices using a linearization of the model
around the mean of the prior distribution. The second
paper focuses on the use of the determinant of MBF to
optimize the design for Bayesian individual estimates.
Several population and Bayesian designs are evaluated
and compared in this study, from which the authors con-
cluded that there is a difference between the optimal
Bayesian and population designs, even if optimal Bayesian
designs sometime involve the same sampling times than the
optimal population design. In the present work, we con-
firmed that optimal Bayesian and population designs are
different for a given model.
With the proposed approach in this publication, shrink-
age optimization can be included in addition to optimiza-
tion of the SE of the population parameters. This
optimization requires the use of compound criteria and
evaluation of the impact of the weight of each criterion on
the design and on the population and individual parameter
estimates (27).
This work also evaluated the expression and the use of
individual MBF to predict SE of the individual parameter
estimates. In all investigated cases the predictions were very
close to the individual SE generated by NONMEM and
MONOLIX. In some cases, the ranges of the individual SE
estimated by MONOLIX were found to be higher than in
NONMEM. This was especially the case for the volume of
distribution of the more complex PK model. This may be
due to the fact that MONOLIX computes the variance of
the conditional distribution without linearization.
Although the predicted and observed shrinkages were
similar, we observed minor discrepancies for example 2.
For 2 or 4 samples per subject, predicted shrinkages on
CL and V1 were below the observed values. This was not
the case when individual parameters were estimated by
MONOLIX. Considering MIBF computation of SE in this
more complex model, predictions were close to the estimat-
ed results using NONMEM for all parameters except V1.
SE distributions estimated using MONOLIX were wider
than those with NONMEM, with a similar median. We
hypothesized earlier in this paper that these differences stem
from the different SE computation methods used in
NONMEM and MONOLIX, but further investigation is
warranted.
Fig. 3 Example 1: predicted shrinkage value vs observed shrinkage values for simulation A (2 left columns) and simulation B (right column). Each number
defines the number of samples per subject. The black line represents the identity line. Boxplot for simulation B represents the 1,000 observed shrinkage
values for each design.
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In this paper, we made the assumption of a diagonal Ω
matrix for the sake of simplicity. The same formula would
hold for a non-diagonal matrix.
Prediction of shrinkage was evaluated for example 2,
changing the variances of the random effects to smaller and
more reasonable value of 30% compared with the true base
model developed by Frey et al., which estimated 110% vari-
ability on V2. However, although the FO approximation used
to computeMBF performs very well for reasonable variability,
increase in variability worsened prediction, especially for very
large variabilities as shown in the Supplementary Materials.
This is certainly a limitation of the FO approximation, which
is known to be appropriate only if the variances of the random
effects are relatively small (28,29).
In example 1 - simulation A and example 2, population
parameters were set to their true value. With this method,
Fig. 4 Example 1: Predicted and estimated individual SE of clearance and volume. Blue boxplots are predicted SE by MIBF
−1, red ones are SE estimated by
NONMEM and green by MONOLIX. Black diagonal cross “X” is the value predicted by MBF
−1 using FO approximation.
Fig. 5 Example 2: predicted
shrinkage vs observed shrinkage
according to the number of
samples per subject (2, 4, 9 or R
for 10). The black line represents
the identity line.
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we wanted to avoid any bias or distribution discrepancies in
parameters distribution. Indeed, the goal of this simulation
was to evaluate the prediction of shrinkage and individual
SE for some given estimated individual parameters, with the
smallest possible external influence such as population pa-
rameters estimation. However, to explore what could hap-
pen in a real estimation context, we also explored the
deviation between predicted shrinkage computed for true
simulation values and the observed shrinkage obtained after
a first step in estimation of the population parameters and a
second Bayesian step in estimation of the individual param-
eters. This exploration showed a good agreement between
predictions and observations. Nevertheless, we acknowl-
edge that the example used was rather simple with a
fully informative design (combined sparse and rich ele-
mentary design with 120 and 50 subjects), and that
further investigations with more complex models as of-
ten encountered in drug development associated with
rather sparse designs should be performed.
Lastly, Savic et al. (21) showed that high shrinkage can
induce or hide a correlation between parameters and covar-
iates. A hypothesis of no correlation could therefore be
falsely accepted when this correlation does not truly exist.
One perspective would be to link the shrinkage with the
power of the test used to detect that covariate. That could
minimize the risk of falsely detected (or not detected) influ-
ence of some covariate due to uninformative design. Future
work should then focus on the impact of the precision of
estimates on covariate selection and on the link between
shrinkage and the power of the test for covariate selection.
CONCLUSION
We introduce a methodology based on the Fisher informa-
tion Matrix to predict accurately the shrinkage associated
with a given design in non-linear mixed-effect models.
Bayesian evaluation will soon be implemented in PFIM to
allow an easy prediction of shrinkage when planning phar-
macokinetic studies. It opens up perspectives for better
design and more relevant estimates of the individual phar-
macokinetic parameters from population analysis.
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